{"aliases":[{"type":"Abbreviation","name":"TNX-650"},{"type":"Synonym","name":"monoclonal antibody TNX-650"},{"type":"Synonym","name":"immunoglobulin G4, anti-(human interleukin 13) (human-mouse monoclonal MILR1444a gamma-4-chain), disulfide with human-mouse monoclonal MILR1444a kappa-chain, dimer"},{"type":"CodeName","name":"PRO301444"},{"type":"CodeName","name":"MILR1444A"},{"type":"Synonym","name":"anti-IL-13 humanized monoclonal antibody TNX-650"},{"type":"CASRegistryName","name":"953400-68-5"}],"definition":{"html":"A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation.","text":"A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and inhibits IL-13-mediated pathways. IL-13, a cytokine mainly secreted by type 2 helper T cells, plays a key role in the induction of allergic inflammation."},"drugInfoSummaryLink":null,"nciConceptId":"C87767","nciConceptName":"Lebrikizumab","termId":539362,"name":"lebrikizumab","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lebrikizumab"}